Work

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

Year: 2015

Type: article

Source: The Lancet

DOI: 10.1016/s0140-6736(14)61836-5

Authors: Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, Jonathan L Halperin, Günter Breithardt, Daniel E Singer, Kenneth W Mahaffey, Graeme J Hankey, Scott D Berkowitz, Christopher C Nessel, Keith A A Fox, Robert M Califf, Jonathan P Piccini, Manesh R Patel

Institutions: Duke Medical Center, Duke Clinical Research Institute, University of Münster, University Hospital Münster, Harvard University, Massachusetts General Hospital, Stanford Medicine, Stanford University, The University of Western Australia, Bayer (United States), Janssen Research & Development (United States), Edinburgh Royal Infirmary, University of Edinburgh

Language: English

Topic: Atrial Fibrillation Management and Outcomes

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: European Society of Cardiology, Duke Clinical Research Institute

OpenAlex ID: W2165834301

FWCI: 17.41

Cites: 28

Cited by: 145

Related to: 10